In Brief: Canagliflozin and Lower Limb Amputations

Date: September 21, 2020 Issue #: 1607Summary: The FDA has removed a boxed warning from the labeling of products containing the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (Invokana,Invokamet,Invokamet XR) that described an increased risk of lower limb amputation associated with use of the drug. Package inserts for canagliflozin products still contain a standard warning about a risk of lower limb amputation.

http://secure.medicalletter.org/TML-article-1607c

Source: The Medical Letter - September 11, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research